About Eukaryotic translation initiation factor 3 subunit J
Eukaryotic translation initiation factor 3 subunit J (EIF3J) is a protein
from Homo sapiens identified by UniProt accession
O75822, 258 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 3 subunit J |
|---|
| UniProt accession | O75822 |
|---|
| Gene | EIF3J |
|---|
| Organism | Homo sapiens |
|---|
| Length | 258 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (30)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.36
- hereditary sensory and autonomic neuropathy with spastic paraplegia · score 0.16
- high density lipoprotein cholesterol measurement · score 0.14
- triglyceride measurement · score 0.14
- alcohol drinking · score 0.14
- alcohol consumption measurement · score 0.14
- hereditary spastic paraplegia 11 · score 0.12
- hereditary spastic paraplegia · score 0.12
- eating disorder · score 0.10
- lean body mass · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75822-F1 | alphafold | PREDICTED | 68.08 | — |
Amino-acid sequence (258 residues)
MAAAAAAAGD SDSWDADAFS VEDPVRKVGG GGTAGGDRWE GEDEDEDVKD NWDDDDDEKK EEAEVKPEVK ISEKKKIAEK IKEKERQQKK RQEEIKKRLE EPEEPKVLTP EEQLADKLRL KKLQEESDLE LAKETFGVNN AVYGIDAMNP SSRDDFTEFG KLLKDKITQY EKSLYYASFL EVLVRDVCIS LEIDDLKKIT NSLTVLCSEK QKQEKQSKAK KKKKGVVPGG GLKATMKDDL ADYGGYDGGY VQDYEDFM
Explore Eukaryotic translation initiation factor 3 subunit J with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets